International Study for Treatment of High Risk Childhood Relapsed ALL 2010
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Rituximab Combining Bortezomib Versus Rituximab in Management of ITP
- Status
- UNKNOWN
- Phase
- PHASE3
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
- Status
- COMPLETED
- Phase
- PHASE4
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
- Status
- COMPLETED
- Phase
- PHASE2
BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients
- Status
- COMPLETED
- Phase
- NA
Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)
- Status
- RECRUITING
- Phase
- NA
Bortezomib in Intrahepatic Cholangiocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE3
Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders.
- Status
- COMPLETED
- Phase
- N/A
Study of VTD in Waldenstrom's Macroglobulinemia
- Status
- UNKNOWN
- Phase
- PHASE2
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE3
MUK Nine b: OPTIMUM Treatment Protocol
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis
- Status
- WITHDRAWN
- Phase
- PHASE2